Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for long-term investors to capitalize now.

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

Denmark's Export and Investment Fund (EIFO) and the Novo Nordisk Foundation (NNF) are set to invest €80 million ($92.93m) to ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Everybody wants their hands on NVIDIA's GPUs, with the AI favorite continuing to ink fresh deals and collaborate with many ...

A nationwide Danish study finds that the incidence of paediatric stroke is rising among boys while remaining stable among ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

Designed by Sylvia Richards, the mass-timber addition to Adimab's Lebanon campus is sensitive to the lushly forested wetland ...

Significant’ weight returned weeks after stopping drug, say researchers who advise patients to adjust expectations.

In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55% drop in shares of Novo Nordisk in the last year, related in part to concerns over competition in ...

Older adults and women using Wegovy for obesity management may be more likely to lose lean mass, although increasing protein intake may help protect against lean mass loss, according to a speaker.